NCCN Pharmacy Updates: Novel Agents for the Treatment of Relapsed/Refractory Multiple Myeloma
Several new options have recently been approved for the treatment of relapsed/refractory multiple myeloma. Pharmacists should be aware of the new data and recommendations surrounding these novel agents and how they relate to improvements in patient survival and quality of life.
Category
  • Multiple Myeloma
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Event date June 9, 2021